UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population

Alimentary pharmacology & therapeutics, 2017-08, Vol.46 (4), p.447-456

2017

Volltextzugriff (PDF)

Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (6), p.730-737

2018

Volltextzugriff (PDF)

Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments

Alimentary pharmacology & therapeutics, 2014-02, Vol.39 (3), p.254-269

2014

Volltextzugriff (PDF)

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

Alimentary pharmacology & therapeutics, 2017-09, Vol.46 (6), p.617-627

2017

Volltextzugriff (PDF)

Meta‐analysis: the efficacy of anti‐viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B‐related hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2011-05, Vol.33 (10), p.1104-1112

2011

Volltextzugriff (PDF)

Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2013-03, Vol.37 (5), p.517-526

2013

Volltextzugriff (PDF)

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B

Journal of viral hepatitis, 2009-01, Vol.16 (1), p.36-44

2009

Volltextzugriff (PDF)

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.532-539

2014

Volltextzugriff (PDF)

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Alimentary pharmacology & therapeutics, 2017-11, Vol.46 (10), p.1001-1010

2017

Volltextzugriff (PDF)

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Alimentary pharmacology & therapeutics, 2010-12, Vol.32 (11‐12), p.1323-1331

2010

Volltextzugriff (PDF)

Significant positive association of endotoxemia with histological severity in 237 patients with non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (2), p.175-182

2017

Volltextzugriff (PDF)

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations

Alimentary pharmacology & therapeutics, 2014-04, Vol.39 (8), p.883-893

2014

Volltextzugriff (PDF)

Predictors of relapse in chronic hepatitis B after discontinuation of anti‐viral therapy

Alimentary pharmacology & therapeutics, 2011-08, Vol.34 (3), p.344-352

2011

Volltextzugriff (PDF)

Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2008-11, Vol.28 (9), p.1067-1077

2008

Volltextzugriff (PDF)

Non‐invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (2), p.197-208

2014

Volltextzugriff (PDF)

Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B‐related hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2016-04, Vol.43 (7), p.802-813

2016

Volltextzugriff (PDF)

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years

Alimentary pharmacology & therapeutics, 2012-06, Vol.35 (11), p.1326-1335

2012

Volltextzugriff (PDF)

Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B

Gut, 2009-01, Vol.58 (1), p.111-117

2009

Volltextzugriff (PDF)

Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects

Alimentary pharmacology & therapeutics, 2017-05, Vol.45 (9), p.1213-1224

2017

Volltextzugriff (PDF)

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.731-740

2015

Volltextzugriff (PDF)

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1057-1066

2012

Volltextzugriff (PDF)

Serum interferon‐inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (1), p.145-153

2016

Volltextzugriff (PDF)

Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B

Journal of viral hepatitis, 2014-12, Vol.21 (12), p.825-834

2014

Volltextzugriff (PDF)

Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. Authors' reply

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.1037-1038

2018

Volltextzugriff (PDF)

Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (1), p.96-101

2016

Volltextzugriff (PDF)

1 – 25 von 799

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(706)
Mit Volltextzugriff
(703)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(798)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population

Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B

Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

Meta‐analysis: the efficacy of anti‐viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B‐related hepatocellular carcinoma

Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Significant positive association of endotoxemia with histological severity in 237 patients with non‐alcoholic fatty liver disease

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations

Predictors of relapse in chronic hepatitis B after discontinuation of anti‐viral therapy

Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma

Non‐invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B

Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B‐related hepatocellular carcinoma

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years

Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B

Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

Serum interferon‐inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B

Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B

Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. Authors' reply

Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong

Suchergebnisse filtern